Back to top

BeOne Medicines Halts Early BGB-21447 Cancer Trial: What Investors Should Watch

BeOne Medicines ($ONC) announced an update on their ongoing clinical study. The Phase 1/1b study titled “A Phase 1/1b Open-Label Dose-Escalation an...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

BeOne Medicines Ltd. - Sponsored ADR (ONC)